All Oncology News

Felipe Batalini, MD, and Alberto Montero, MD, MBA, CPHQ, detail how allosteric inhibitors targeting PIK3CA such as STX-478 may reduce toxicities seen with orthosteric inhibitors.

The director of the Hematology/Oncology Fellowship Training Program at Fox Chase Cancer Center discusses palliative care training for hematology/oncology fellows and highlights a pilot study aimed at improving this area of training.

Omid Hamid, MD, discusses recent advances in the melanoma treatment landscape and highlights the 21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®.

European approval is no longer being sought for Dato-DXd in advanced nonsquamous non–small cell lung cancer.

Confidence, support, and hard work paved the way for an exceptionally successful career for Edward S. Kim, MD, MBA, who has a cemented mission in diversifying clinical trials and improving quality of life.

In a Peer Exchange, HCC experts discussed how new data from the HIMALAYA, LEAP-012, EMERALD-1, and IMbrave050 trials could be used to optimize treatment.

Matthew Hadfield, DO, discusses findings from a phase 2 study that used tocilizumab to reduce toxicities with immune checkpoint inhibitors in melanoma.

R. Lor Randall, MD, FACS, discusses the construction and preclinical utility of spheroid models for drug development in osteosarcoma.

Jonathan Wesley Riess, MD, MS, details the potential for ivonescimab in NSCLC after improving PFS vs pembrolizumab in the HARMONi-2 trial.

Nivolumab plus ipilimumab has been approved in Europe for the frontline treatment of adult patients with MSI-H or dMMR metastatic colorectal cancer.

The NCCN Guidelines have been updated to include neratinib for HER2-mutated recurrent/metastatic cervical cancer in the second line or later.

The FDA has granted priority review to the NDA seeking the approval for taletrectinib in ROS1-positive advanced non–small cell lung cancer.

Findings point to a biomarker that may give a “head start” to triple-negative breast cancer in Black women.

CheckMate 73L missed its primary end point of PFS in advanced unresectable stage III non–small cell lung cancer.

With a focus on closing gaps in cancer care for underserved populations, Joseph A. Sparano, MD, FACP, always strives to put patients first—a quality that has become a hallmark of his research and career in oncology.

Aparna Parikh, MD, discussed novel agents that are currently at play in the mutated, metastatic colorectal cancer treatment field.

The FDA awards accelerated approval to encorafenib regimen in BRAF V600E+ CRC, ensartinib wins approval in ALK+ non–small cell lung cancer, and more.

The neoadjuvant/adjuvant pembrolizumab and chemotherapy combination was approved by the FDA in October 2023 for use in this patient population.

Adding dostarlimab to chemotherapy and niraparib maintenance improved progression-free survival in first-line advanced ovarian cancer.

The addition of pegcrisantaspase to venetoclax may overcome resistance to prior BCL-2 inhibitor–based regimens for patients with relapsed/refractory AML.

The FDA has approved encorafenib plus cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation.

Retifanlimab represents a promising agent in the squamous cell anal carcinoma field and additional research is needed to improve outcomes for patients.

China's NMPA has approved taletrectinib for locally advanced or metastatic ROS1-positive non–small cell lung cancer after a previous ROS1 TKI.

Uproleselan plus chemotherapy did not improved overall survival in relapsed/refractory acute myeloid leukemia.

John Mascarenhas, MD, discusses navtemadlin's mechanism of action and its potential to shift the myelofibrosis treatment landscape

A preclinical study showed gilteritinib can strengthen CAR T-cell therapy in two high-risk pediatric leukemias.

Zongertinib demonstrated durable efficacy in patients with pretreated advanced HER2-mutant non–small cell lung cancer.

Olverembatinib demonstrated preliminary efficacy and was well tolerated in patients with heavily pretreated chronic-phase myeloid leukemia.

Fox Chase Cancer Center researchers have identified a pretreatment protocol that reduces adverse effects for the drug motixafortide.

Second-line lenvatinib had clinically meaningful efficacy in patients with advanced HCC after progression on atezolizumab plus bevacizumab.